Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

The Almond Yogurt Study (AYS) (AYS)

16 de novembro de 2026 atualizado por: Amanda Wright, Ph.D., University of Guelph

The Impact of Almond Food Structure in a Standardized Yogurt Breakfast Meal on Gastric Emptying, Oral Processing Behaviours, Appetite-Regulating Hormones, Postprandial Metabolism, and Subjective Satiety: A Randomized Crossover Trial

The goal of this clinical trial is to explore how almond food structure influences gastric emptying rates when consumed by healthy adult women as part of a standardized breakfast meal. The main questions it aims to answer are:

  • Does the structure of almonds (whole, chopped, buttered) influence gastric emptying ?
  • What is the correlation between chewing behaviour, gastric emptying, and changes in postprandial triacylglycerols and satiety (hormones and ratings) within the context of an increasingly disrupted nut matrix.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Intervenção / Tratamento

Descrição detalhada

This study is investigating how the structure of almonds (whole, chopped, buttered) as part of a yogurt-based breakfast meal influences gastric emptying and postprandial metabolism. Over three randomized visits, fasted healthy adult female participants will arrive at the research centre where an iv-catheter will be inserted for serial blood sampling over 6 hours for analysis of plasma triacylglycerols, GLP-1, CCK, glucose, and insulin. Participants will consume each meal while being video recorded to quantify chewing frequency and eating time. Paper questionnaires will periodically assess participants' eating experiences and hunger sensations throughout the visit (e.g., exertion, liking, hunger, fullness). Gastric ultrasonography will be used to visualize and quantify the cross-sectional area of the gastric antrum so that changes in gastric volume can be tracked over time. Overall, this study aims to determine how almond form, as an example of food structure, influences chewing, gastric emptying, satiety and postprandial metabolism.

Tipo de estudo

Intervencional

Inscrição (Estimado)

25

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Ontario
      • Guelph, Ontario, Canadá, N1G 2G4
        • Department of Human Health Sciences
        • Contato:
        • Contato:
          • Alison M Duncan, PhD
        • Investigador principal:
          • Amanda J Wright, PhD

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 45 anos (Adulto)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Inclusion Criteria:

  • Healthy female adults aged 18-45 years.
  • Body Mass Index (BMI) between 18.5-27.9 kg/m2, or waist circumference of less than 88 cm
  • Visible gastric antrum on ultrasound
  • No known food allergies or sensitivities
  • Non restrained eaters (TFEQ, see below)
  • No history of gastrointestinal diseases that may interfere with eating behavior or digestion
  • Not on medications that affect appetite (including GLP-1 agonists), digestion, blood sugar regulation, saliva production, or chewing
  • Stable medication use
  • Non-smokers
  • Not gained or lost significant weight during the past 3 months
  • Regular monthly menstrual cycles
  • Not pregnant, lactating or post-menopausal

Exclusion Criteria:

  • Diabetes or other metabolic disorders affecting glycemia and overall cardiometabolic health
  • Blood pressure > 140/90 mm Hg
  • Any food allergies, intolerances, or sensitivities
  • Pregnant or breastfeeding
  • Participation in another clinical trial
  • Excessive alcohol consumption (more than 14 drinks per week)
  • Smokers or those with a smoking history of more than 10 years
  • Regular use of recreational drugs (e.g., marijuana, ecstasy, LSD, magic mushrooms, etc.)
  • Restrained eater (>16) as defined by the questionnaire at screening (Three-Factor Eating Questionnaire, Stunkard et al., 1985)
  • Unusual sleep patterns
  • Irregular breakfast consumption
  • Recent weight changes, or intended weight loss or gain; lost/gained 10% of body weight within the last 6 months
  • Food allergies/sensitivities or any life-threatening allergies
  • Using medications known to affect appetite, digestion, blood sugar regulation, or chewing/swallowing (excluding oral contraceptives).
  • Experiences dry mouth in general or due to medication side effects
  • Inability to adhere to study protocols
  • Not comfortable providing IV-line blood samples
  • Not comfortable providing ultrasound scans
  • Not comfortable being video recorded while eating
  • Avoids consuming almonds/yogurt in general
  • Avoids eating hard foods to prevent dental fractures

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Ciência básica
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição cruzada
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Whole - Chopped - Buttered

Participants consume 115 g vanilla yogurt with 60 g whole almonds at the first intervention visit, chopped almonds at the second intervention visit, and almonds processed into almond butter at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Experimental: Whole - Buttered - Chopped

Participants consume 115 g vanilla yogurt with 60 g whole almonds at the first intervention visit, buttered almonds at the second intervention visit, and chopped almonds at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Experimental: Buttered - Whole - Chopped

Participants consume 115 g vanilla yogurt with 60 g buttered almonds at the first intervention visit, whole almonds at the second intervention visit, and chopped almonds at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Experimental: Buttered - Chopped - Whole

Participants consume 115 g vanilla yogurt with 60 g buttered almonds at the first intervention visit, chopped almonds at the second intervention visit, and whole almonds at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Experimental: Chopped - Buttered - Whole

Participants consume 115 g vanilla yogurt with 60 g chopped almonds at the first intervention visit, buttered almonds at the second intervention visit, and whole almonds at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Experimental: Chopped - Whole - Buttered

Participants consume 115 g vanilla yogurt with 60 g chopped almonds at the first intervention visit, whole almonds at the second intervention visit, and buttered almonds at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Gastric emptying half-time
Prazo: At each study visit, based on assessments at 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated from ultrasound imaging of the gastric antrum cross-sectional area at baseline (fasted) and after consumption of the breakfast meal, in minutes

At each study visit, based on assessments at 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Eating time
Prazo: From 0 minutes until the end of eating the breakfast meal

The time to consume the breakfast meal based on video recordings, in minutes

From 0 minutes until the end of eating the breakfast meal
Changes from baseline in postprandial satiety visual analogue scale ratings
Prazo: 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Paper questionnaire scale ratings (in mm) of Hunger, Fullness, Prospective Consumption, and Desire to Eat where each is 100 mm ranging from 0 (minimum) to 100 (maximum). For example, 0 = Not at all Hungry and 100 = As Hungry as Possible.

0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Changes from baseline in plasma triacylglycerol concentration
Prazo: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on analysis of serial blood draws, in mmol/L

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Triacylglycerol response - incremental area under the curve (AUC)
Prazo: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on baseline and postprandial plasma concentrations

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Changes from baseline in plasma GLP-1 concentration
Prazo: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on analysis of serial blood draws, in pg/mL

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
GLP-1 response - incremental area under the curve (AUC)
Prazo: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on baseline and postprandial plasma concentrations

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Changes from baseline in plasma CCK concentration
Prazo: 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on analysis of serial blood draws, in pmol/L

0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
CCK response - incremental area under the curve (AUC)
Prazo: 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on baseline and postprandial plasma concentrations

0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Changes from baseline in gastric volume
Prazo: 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on ultrasound imaging of the gastric antrum cross-sectional area at baseline (fasted) and after eating the breakfast meal, in mL

0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Gastric volume - incremental area under the curve (AUC)
Prazo: 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on ultrasound imaging of the gastric antrum cross-sectional area at baseline (fasted) and after eating the breakfast meal

0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Borg rating of perceived exertion
Prazo: Immediately after the breakfast meal is consumed

Participant paper scale rating of effort required to chew the breakfast meal where 0 = No effort at all and 10 = Very very severe chewing effort

Immediately after the breakfast meal is consumed
Changes from baseline in plasma blood glucose concentration
Prazo: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on analysis of serial blood draws, in mmol/mL

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Glucose response - incremental area under the curve (AUC)
Prazo: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on baseline and postprandial plasma concentrations

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Changes from baseline in plasma blood insulin concentration
Prazo: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on analysis of serial blood draws, in pmol/mL

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Insulin response - Area under the curve (AUC)
Prazo: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on baseline and postprandial plasma concentrations

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Product liking and perceived attributes
Prazo: Immediately after eating the breakfast meal

Participant paper scale questionnaire ratings

Immediately after eating the breakfast meal
Eating rate
Prazo: From 0 minutes until the end of eating the breakfast meal

Calculated from video recordings of eating session, combining meal portion consumed (in grams) and eating time (minutes), grams/minute

From 0 minutes until the end of eating the breakfast meal
Number of chews
Prazo: From 0 minutes until the end of eating the breakfast meal

Determined by count from video recordings of each eating session

From 0 minutes until the end of eating the breakfast meal

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

15 de novembro de 2026

Conclusão Primária (Estimado)

15 de dezembro de 2027

Conclusão do estudo (Estimado)

19 de dezembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

29 de outubro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

16 de novembro de 2026

Primeira postagem (Real)

18 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

16 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • ID3014
  • 400819 (Número de outro subsídio/financiamento: Natural Sciences & Engineering Research Council of Canada)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Descrição do plano IPD

Although we are not required to make this data available, we are currently working to understand how to do this in a safe way, as per our institutional guidelines. As we learn more, we may pursue this. We are obtaining consent from study participants for this option.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .